A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 300 participants.

Also called NCT06731075

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
  • Oramed, Ltd. Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06731075
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06731075. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-15 (anticipated); primary completion 2027-04-25 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
ORMD-0801 8 mg
Intervention (Other)
Placebo capsule
Intervention (Drug)
ORMD-0801 16 mg
Lead sponsor
Oramed, Ltd. (class: industry)
Collaborator
InClin, Inc. (class: industry)

Record details

Record id
cardio:ct-nct06731075
Content hash
63264bc09ed00ac2c479358b168131ae40338c9e5b09061a5714c24676285dcc